Principles of antibody-mediated TNF receptor activation

Cell Death and Differentiation

Volumn 22, Issue 11, 2015, Pages 1727-1741

  Wajant, H ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; LIGAND; RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; ANTIBODY;

HUMAN; NONHUMAN; OLIGOMERIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; STIMULATION; ANIMAL; CELL MEMBRANE; METABOLISM; PROTEIN MULTIMERIZATION;

ANIMALS; ANTIBODIES; CELL MEMBRANE; HUMANS; PROTEIN MULTIMERIZATION; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84943197218     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.109     Document Type: Review

References (164)

1. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002; 27: 19-26.
2. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501.
3. Chattopadhyay K, Ramagopal UA, Brenowitz M, Nathenson SG, Almo SC. Evolution of GITRL immune function: murine GITRL exhibits unique structural and biochemical properties within the TNF superfamily. Proc Natl Acad Sci USA 2008; 105: 635-640.
4. Zhou Z, Tone Y, Song X, Furuuchi K, Lear JD, Waldmann H et al. Structural basis for ligand-mediated mouse GITR activation. Proc Natl Acad Sci USA 2008; 105: 641-645.
5. Androlewicz MJ, Browning JL, Ware CF. Lymphotoxin is expressed as a heteromeric complex with a distinct 33-kDa glycoprotein on the surface of an activated human T cell hybridoma. J Biol Chem 1992; 267: 2542-2547.
6. Day ES, Cachero TG, Qian F, Sun Y, Wen D, Pelletier M et al. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 2005; 44: 1919-1931.
7. Nelson CA, Warren JT, Wang MW, Teitelbaum SL, Fremont DH. RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure 2012; 20: 1971-1982.
8. Holler N, Kataoka T, Bodmer JL, Romero P, Romero J, Deperthes D et al. Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors. J Immunol Methods 2000; 237: 159-173.
9. Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, Lynch D et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000; 288: 2354-2357.
10. Garibyan L, Lobito AA, Siegel RM, Call ME, Wucherpfennig KW, Geha RS. Dominant-negative effect of the heterozygous C104R TACI mutation in common variable immunodeficiency (CVID). J Clin Invest 2007; 117: 1550-1557.
11. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288: 2351-2354.
12. Neumann S, Hasenauer J, Pollak N, Scheurich P. Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes. J Biol Chem 2014; 289: 16576-16587.
13. Papoff G, Hausler P, Eramo A, Pagano MG, Di Leve G, Signore A et al. Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor. J Biol Chem 1999; 274: 38241-38250.
14. Cao J, Meng F, Gao X, Dong H, Yao W. Expression and purification of a natural N-terminal pre-ligand assembly domain of tumor necrosis factor receptor 1 (TNFR1 PLAD) and preliminary activity determination. Protein J 2011; 30: 281-289.
15. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83: 793-802.
16. Grell M, Wajant H, Zimmermann G, Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci USA 1998; 95: 570-575.
17. Bossen C, Cachero TG, Tardivel A, Ingold K, Willen L, Dobles M et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 2008; 111: 1004-1012.
18. Ingold K, Zumsteg A, Tardivel A, Huard B, Steiner QG, Cachero TG et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005; 201: 1375-1383.
19. Fick A, Lang I, Schafer V, Seher A, Trebing J, Weisenberger D et al. Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14). J Biol Chem 2012; 287: 484-495.
20. Lang I, Fick A, Schafer V, Giner T, Siegmund D, Wajant H. Signaling active CD95 receptor molecules trigger co-translocation of inactive CD95 molecules into lipid rafts. J Biol Chem 2012; 287: 24026-24042.
21. Wajant H. Principles and mechanisms of CD95 activation. Biol Chem 2014; 395: 1401-1416.
22. Roos C, Wicovsky A, Muller N, Salzmann S, Rosenthal T, Kalthoff H et al. Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J Immunol 2010; 185: 1593-1605.
23. Baccam M, Bishop GA. Membrane-bound CD154, but not CD40-specific antibody, mediates NF-kappaB-independent IL-6 production in B cells. Eur J Immunol 1999; 29: 3855-3866.
24. Salzmann S, Seher A, Trebing J, Weisenberger D, Rosenthal A, Siegmund D et al. Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity. J Biol Chem 2013; 288: 13455-13466.
25. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S. TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem 2003; 278: 36005-36012.
26. Varfolomeev E, Goncharov T, Maecker H, Zobel K, Komuves LG, Deshayes K et al. Cellular inhibitors of apoptosis are global regulators of NF-kappaB and MAPK activation by members of the TNF family of receptors. Sci Signal 2012; 5: ra22.
27. Dueber EC, Schoeffler AJ, Lingel A, Elliott JM, Fedorova AV, Giannetti AM et al. Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination. Science 2011; 334: 376-380.
28. Mace PD, Smits C, Vaux DL, Silke J, Day CL. Asymmetric recruitment of cIAPs by TRAF2. J Mol Biol 2010; 400: 8-15.
29. Park YC, Burkitt V, Villa AR, Tong L,Wu H. Structural basis for self-association and receptor recognition of human TRAF2. Nature 1999; 398: 533-538.
30. Zheng C, Kabaleeswaran V, Wang Y, Cheng G, Wu H. Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation. Mol Cell 2010; 38: 101-113.
31. Feltham R, Bettjeman B, Budhidarmo R, Mace PD, Shirley S, Condon SM et al. Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization. J Biol Chem 2011; 286: 17015-17028.
32. Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, Schneider P et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol 2008; 182: 171-184.
33. Wicovsky A, Salzmann S, Roos C, Ehrenschwender M, Rosenthal T, Siegmund D et al. TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling. Cell Death Differ 2009; 16: 1445-1459.
34. Dickens LS, Boyd RS, Jukes-Jones R, Hughes MA, Robinson GL, Fairall L et al. A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death. Mol Cell 2012; 47: 291-305.
35. Esposito D, Sankar A, Morgner N, Robinson CV, Rittinger K, Driscoll PC. Solution NMR investigation of the CD95/FADD homotypic death domain complex suggests lack of engagement of the CD95 C terminus. Structure 2010; 18: 1378-1390.
36. Schleich K, Warnken U, Fricker N, Ozturk S, Richter P, Kammerer K et al. Stoichiometry of the CD95 death-inducing signaling complex: experimental and modeling evidence for a death effector domain chain model. Mol Cell 2012; 47: 306-319.
37. Scott FL, Stec B, Pop C, Dobaczewska MK, Lee JJ, Monosov E et al. The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature 2009; 457: 1019-1022.
38. Wang L, Yang JK, Kabaleeswaran V, Rice AJ, Cruz AC, Park AY et al. The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations. Nat Struct Mol Biol 2010; 17: 1324-1329.
39. Martin-Villalba A, Llorens-Bobadilla E,Wollny D. CD95 in cancer: tool or target? Trends Mol Med 2013; 19: 329-335.
40. Henkler F, Behrle E, Dennehy KM, Wicovsky A, Peters N, Warnke C et al. The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability. J Cell Biol 2005; 168: 1087-1098.
41. O'Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009; 461: 659-663.
42. de Bruyn M, Bremer E, Helfrich W. Antibody-based fusion proteins to target death receptors in cancer. Cancer Lett 2013; 332: 175-183.
43. Wajant H, Gerspach J, Pfizenmaier K. Engineering death receptor ligands for cancer therapy. Cancer Lett 2013; 332: 163-174.
44. Hendriks J, Planelles L, de Jong-Odding J, Hardenberg G, Pals ST, Hahne M et al. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ 2005; 12: 637-648.
45. Mhawech-Fauceglia P, Kaya G, Sauter G, McKee T, Donze O, Schwaller J et al. The source of APRIL up-regulation in human solid tumor lesions. J Leukoc Biol 2006; 80: 697-704.
46. Gerspach J, Muller D, Munkel S, Selchow O, Nemeth J, Noack M et al. Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinasemediated processing of a TNF prodrug. Cell Death Differ 2006; 13: 273-284.
47. Beutler BA, Milsark IW, Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol 1985; 135: 3972-3977.
48. Flick DA, Gifford GE. Pharmacokinetics of murine tumor necrosis factor. J Immunopharmacol 1986; 8: 89-97.
49. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001; 299: 31-38.
50. Engelmann H, Holtmann H, Brakebusch C, Avni YS, Sarov I, Nophar Y et al. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem 1990; 265: 14497-14504.
51. Grell M, Scheurich P, Meager A, Pfizenmaier K. TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis. Lymphokine Cytokine Res 1993; 12: 143-148.
52. Espevik T, Brockhaus M, Loetscher H, Nonstad U, Shalaby R. Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor. J Exp Med 1990; 171: 415-426.
53. Dhein J, Daniel PT, Trauth BC, Oehm A, Moller P, Krammer PH. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol 1992; 149: 3166-3173.
54. Alderson MR, Tough TW, Braddy S, Davis-Smith T, Roux E, Schooley K et al. Regulation of apoptosis and T cell activation by Fas-specific mAb. Int Immunol 1994; 6: 1799-1806.
55. Fadeel B, Thorpe CJ, Yonehara S, Chiodi F. Anti-Fas IgG1 antibodies recognizing the same epitope of Fas/APO-1 mediate different biological effects in vitro. Int Immunol 1997; 9: 201-209.
56. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169: 1747-1756.
57. Bjorck P, Braesch-Andersen S, Paulie S. Antibodies to distinct epitopes on the CD40 molecule co-operate in stimulation and can be used for the detection of soluble CD40. Immunology 1994; 83: 430-437.
58. Schwabe RF, Hess S, Johnson JP, Engelmann H. Modulation of soluble CD40 ligand bioactivity with anti-CD40 antibodies. Hybridoma 1997; 16: 217-226.
59. Gravestein LA, Nieland JD, Kruisbeek AM, Borst J. Novel mAbs reveal potent co-stimulatory activity of murine CD27. Int Immunol 1995; 7: 551-557.
60. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005; 92: 1430-1441.
61. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7: 954-960.
62. Li J, Knee DA, Wang Y, Zhang Q, Johnson JA, Cheng J et al. LBY135, a novel anti-DR5 agonistic antibody induces tumor cell-specific cytotoxic activity in human colon tumor cell lines and xenografts. Drug Dev Res2008; 69: 69-82.
63. Natoni A, MacFarlane M, Inoue S, Walewska R, Majid A, Knee D et al. TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Br J Haematol 2007; 139: 568-577.
64. Yada A, Yazawa M, Ishida S, Yoshida H, Ichikawa K, Kurakata S et al. A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Ann Oncol 2008; 19: 1060-1067.
65. Zhang L, Zhang X, Barrisford GW, Olumi AF. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett 2007; 251: 146-157.
66. Michaelson JS, Amatucci A, Kelly R, Su L, Garber E, Day ES et al. Development of an Fn14 agonistic antibody as an anti-tumor agent. MAbs 2011; 3: 362-375.
67. Purcell JW, Kim HK, Tanlimco SG, Doan M, Fox M, Lambert P et al. Nuclear Factor kappaB is required for tumor growth inhibition mediated by Enavatuzumab (PDL192), a humanized monoclonal antibody to TweakR. Front Immunol 2014; 4: 505.
68. Trebing J, Lang I, Chopra M, Salzmann S, Moshir M, Silence K et al. A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo. MAbs 2014; 6: 297-308.
69. Madireddi S, Eun SY, Lee SW, Nemcovicova I, Mehta AK, Zajonc DM et al. Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies. J Exp Med 2014; 211: 1433-1448.
70. Xiao S, Jodo S, Sung SS, Marshak-Rothstein A, Ju ST. A novel signaling mechanism for soluble CD95 ligand. Synergy with anti-CD95 monoclonal antibodies for apoptosis and NF-kappaB nuclear translocation. J Biol Chem 2002; 277: 50907-50913.
71. Lemke J, von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death Differ 2014; 21: 1350-1364.
72. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187: 1205-1213.
73. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682.
74. Graves JD, Kordich JJ, Huang TH, Piasecki J, Bush TL, Sullivan T et al. Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. Cancer Cell 2014; 26: 177-189.
75. Tuthill MH, Montinaro A, Zinngrebe J, Prieske K, Draber P, Prieske S et al. TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. Oncogene 2014; 34: 2138-2144.
76. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012; 119: 5640-5649.
77. Pincetic A, Bournazos S, DiLillo DJ, Maamary J,Wang TT, Dahan R et al. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol 2014; 15: 707-716.
78. Lu J, Chu J, Zou Z, Hamacher NB, Rixon MW, Sun PD. Structure of FcgammaRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. Proc Natl Acad Sci USA 2015; 112: 833-838.
79. Mizushima T, Yagi H, Takemoto E, Shibata-Koyama M, Isoda Y, Iida S et al. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells 2011; 16: 1071-1080.
80. Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD. The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem 2001; 276: 16469-16477.
81. Ramsland PA, Farrugia W, Bradford TM, Sardjono CT, Esparon S, Trist HM et al. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J Immunol 2011; 187: 3208-3217.
82. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 2000; 406: 267-273.
83. Bando M, Miyake Y, Shiina M, Wachi M, Nagai K, Kataoka T. Actin cytoskeleton is required for early apoptosis signaling induced by anti-Fas antibody but not Fas ligand in murine B lymphoma A20 cells. Biochem Biophys Res Commun 2002; 290: 268-274.
84. Jodo S, Kung JT, Xiao S, Chan DV, Kobayashi S, Tateno M et al. Anti-CD95-induced lethality requires radioresistant Fcgamma RII+ cells. A novel mechanism for fulminant hepatic failure. J Biol Chem 2003; 278: 7553-7557.
85. Xu Y, Szalai AJ, Zhou T, Zinn KR, Chaudhuri TR, Li X et al. Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J Immunol 2003; 171: 562-568.
86. Li F, Ravetch JV. Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 2011; 333: 1030-1034.
87. White AL, Chan HT, Roghanian A, French RR, Mockridge CI, Tutt AL et al. Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol 2011; 187: 1754-1763.
88. Li F, Ravetch JV. Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcgamma receptor engagement. Proc Natl Acad Sci USA 2012; 109: 10966-10971.
89. Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D et al. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 2011; 19: 101-113.
90. Takeda K, Kojima Y, Ikejima K, Harada K, Yamashina S, Okumura K et al. Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc Natl Acad Sci USA 2008; 105: 10895-10900.
91. Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 2004; 199: 437-448.
92. Li F, Ravetch JV. Antitumor activities of agonistic anti-TNFR antibodies require differential FcgammaRIIB coengagement in vivo. Proc Natl Acad Sci USA 2013; 110: 19501-19506.
93. Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA et al. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptortargeting antibodies. J Exp Med 2013; 210: 1685-1693.
94. Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL. OX40 engagement depletes intratumoral Tregs via activating FcgammaRs, leading to antitumor efficacy. Immunol Cell Biol 2014; 92: 475-480.
95. Huet HA, Growney JD, Johnson JA, Li J, Bilic S, Ostrom L et al. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction. MAbs 2014; 6: 1560-1570.
96. Liu F, Si Y, Liu G, Li S, Zhang J, Ma Y. The tetravalent anti-DR5 antibody without cross-linking direct induces apoptosis of cancer cells. Biomed Pharmacother 2015; 70: 41-45.
97. Papadopoulos KP, Isaacs R, Bilic S, Kentsch K, Huet HA, Hofmann M et al. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody targeting the DR5 receptor. Cancer Chemother Pharmacol 2015; 75: 887-895.
98. White AL, Chan HT, French RR, Willoughby J, Mockridge CI, Roghanian A et al. Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell 2015; 27: 138-148.
99. Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993; 73: 431-445.
100. Eck MJ, Sprang SR. The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J Biol Chem 1989; 264: 17595-17605.
101. Eck MJ, Ultsch M, Rinderknecht E, de Vos AM, Sprang SR. The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution. J Biol Chem 1992; 267: 2119-2122.
102. Naismith JH, Devine TQ, Kohno T, Sprang SR. Structures of the extracellular domain of the type I tumor necrosis factor receptor. Structure 1996; 4: 1251-1262.
103. Naismith JH, Devine TQ, Brandhuber BJ, Sprang SR. Crystallographic evidence for dimerization of unliganded tumor necrosis factor receptor. J Biol Chem 1995; 270: 13303-13307.
104. Mukai Y, Nakamura T, Yoshikawa M, Yoshioka Y, Tsunoda S, Nakagawa S et al. Solution of the structure of the TNF-TNFR2 complex. Sci Signal 2010; 3: ra83.
105. Sudhamsu J, Yin J, Chiang EY, Starovasnik MA, Grogan JL, Hymowitz SG. Dimerization of LTbetaR by LTalpha1beta2 is necessary and sufficient for signal transduction. Proc Natl Acad Sci USA 2013; 110: 19896-19901.
106. Karpusas M, Hsu YM, Wang JH, Thompson J, Lederman S, Chess L et al. 2 A crystal structure of an extracellular fragment of human CD40 ligand. Structure 1995; 3: 1031-1039.
107. An HJ, Kim YJ, Song DH, Park BS, Kim HM, Lee JD et al. Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation. J Biol Chem 2011; 286: 11226-11235.
108. Compaan DM, Hymowitz SG. The crystal structure of the costimulatory OX40-OX40L complex. Structure 2006; 14: 1321-1330.
109. Won EY, Cha K, Byun JS, Kim DU, Shin S, Ahn B et al. The structure of the trimer of human 4-1BB ligand is unique among members of the tumor necrosis factor superfamily. J Biol Chem 2010; 285: 9202-9210.
110. Hymowitz SG, O'Connell MP, Ultsch MH, Hurst A, Totpal K, Ashkenazi A et al. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 2000; 39: 633-640.
111. Cha SS, Kim MS, Choi YH, Sung BJ, Shin NK, Shin HC et al. 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity 1999; 11: 253-261.
112. Cha SS, Sung BJ, Kim YA, Song YL, Kim HJ, Kim S et al. Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J Biol Chem 2000; 275: 31171-31177.
113. Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 1999; 4: 563-571.
114. Mongkolsapaya J, Grimes JM, Chen N, Xu XN, Stuart DI, Jones EY et al. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol 1999; 6: 1048-1053.
115. Lam J, Nelson CA, Ross FP, Teitelbaum SL, Fremont DH. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest 2001; 108: 971-979.
116. Ito S, Wakabayashi K, Ubukata O, Hayashi S, Okada F, Hata T. Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution. J Biol Chem 2002; 277: 6631-6636.
117. Liu C, Walter TS, Huang P, Zhang S, Zhu X, Wu Y et al. Structural and functional insights of RANKL-RANK interaction and signaling. J Immunol 2010; 184: 6910-6919.
118. Luan X, Lu Q, Jiang Y, Zhang S, Wang Q, Yuan H et al. Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin. J Immunol 2012; 189: 245-252.
119. Ta HM, Nguyen GT, Jin HM, Choi J, Park H, Kim N et al. Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis. Proc Natl Acad Sci USA 2010; 107: 20281-20286.
120. Chattopadhyay K, Ramagopal UA, Nathenson SG, Almo SC. 1.8 A structure of murine GITR ligand dimer expressed in Drosophila melanogaster S2 cells. Acta Crystallogr D Biol Crystallogr 2009; 65: 434-439.
121. Chattopadhyay K, Ramagopal UA, Mukhopadhaya A, Malashkevich VN, Dilorenzo TP, Brenowitz M et al. Assembly and structural properties of glucocorticoid-induced TNF receptor ligand: Implications for function. Proc Natl Acad Sci USA 2007; 104: 19452-19457.
122. Zhan C, Yan Q, Patskovsky Y, Li Z, Toro R, Meyer A et al. Biochemical and structural characterization of the human TL1A ectodomain. Biochemistry 2009; 48: 7636-7645.
123. Jin T, Guo F, Kim S, Howard A, Zhang YZ. X-ray crystal structure of TNF ligand family member TL1A at 2.1A. Biochem Biophys Res Commun 2007; 364: 1-6.
124. Zhan C, Patskovsky Y, Yan Q, Li Z, Ramagopal U, Cheng H et al. Decoy strategies: the structure of TL1A:DcR3 complex. Structure 2011; 19: 162-171.
125. Liu W, Zhan C, Cheng H, Kumar PR, Bonanno JB, Nathenson SG et al. Mechanistic basis for functional promiscuity in the TNF and TNF receptor superfamilies: structure of the LIGHT:DcR3 assembly. Structure 2014; 22: 1252-1262.
126. Wallweber HJ, Compaan DM, Starovasnik MA, Hymowitz SG. The crystal structure of a proliferation-inducing ligand, APRIL. J Mol Biol 2004; 343: 283-290.
127. Liu Y, Xu L, Opalka N, Kappler J, Shu HB, Zhang G. Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Cell 2002; 108: 383-394.
128. Karpusas M, Cachero TG, Qian F, Boriack-Sjodin A, Mullen C, Strauch K et al. Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. J Mol Biol 2002; 315: 1145-1154.
129. Oren DA, Li Y, Volovik Y, Morris TS, Dharia C, Das K et al. Structural basis of BLyS receptor recognition. Nat Struct Biol 2002; 9: 288-292.
130. Gordon NC, Pan B, Hymowitz SG, Yin J, Kelley RF, Cochran AG et al. BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligandbinding site. Biochemistry 2003; 42: 5977-5983.
131. Hymowitz SG, Patel DR, Wallweber HJ, Runyon S, Yan M, Yin J et al. Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J Biol Chem 2005; 280: 7218-7227.
132. Pellegrini M, Willen L, Perroud M, Krushinskie D, Strauch K, Cuervo H et al. Structure of the extracellular domains of human and Xenopus Fn14: implications in the evolution of TWEAK and Fn14 interactions. FEBS J 2013; 280: 1818-1829.
133. Liu Y, Hong X, Kappler J, Jiang L, Zhang R, Xu L et al. Ligand-receptor binding revealed by the TNF family member TALL-1. Nature 2003; 423: 49-56.
134. Kim HM, Yu KS, Lee ME, Shin DR, Kim YS, Paik SG et al. Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation. Nat Struct Biol 2003; 10: 342-348.
135. He F, Dang W, Saito K, Watanabe S, Kobayashi N, Guntert P et al. Solution structure of the cysteine-rich domain in Fn14, a member of the tumor necrosis factor receptor superfamily. Protein Sci 2009; 18: 650-656.
136. Hymowitz SG, Compaan DM, Yan M, Wallweber HJ, Dixit VM, Starovasnik MA et al. The crystal structures of EDA-A1 and EDA-A2: splice variants with distinct receptor specificity. Structure 2003; 11: 1513-1520.
137. Kuester M, Kemmerzehl S, Dahms SO, Roeser D, Than ME. The crystal structure of death receptor 6 (DR6): a potential receptor of the amyloid precursor protein (APP). J Mol Biol 2011; 409: 189-201.
138. Ru H, Zhao L, Ding W, Jiao L, Shaw N, Liang W et al. S-SAD phasing study of death receptor 6 and its solution conformation revealed by SAXS. Acta Crystallogr D Biol Crystallogr 2012; 68: 521-530.
139. Gong Y, Cao P, Yu HJ, Jiang T. Crystal structure of the neurotrophin-3 and p75NTR symmetrical complex. Nature 2008; 454: 789-793.
140. Feng D, Kim T, Ozkan E, Light M, Torkin R, Teng KK et al. Molecular and structural insight into proNGF engagement of p75NTR and sortilin. J Mol Biol 2010; 396: 967-984.
141. He XL, Garcia KC. Structure of nerve growth factor complexed with the shared neurotrophin receptor p75. Science 2004; 304: 870-875.
142. Berg D, Lehne M, Muller N, Siegmund D, Munkel S, Sebald W et al. Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ 2007; 14: 2021-2034.
143. Berg D, Stuhmer T, Siegmund D, Muller N, Giner T, Dittrich-Breiholz O et al. Oligomerized tumor necrosis factor-related apoptosis inducing ligand strongly induces cell death in myeloma cells, but also activates proinflammatory signaling pathways. FEBS J 2009; 276: 6912-6927.
144. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005; 280: 2205-2212.
145. Schneider P, Schwenzer R, Haas E, Muhlenbeck F, Schubert G, Scheurich P et al. TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur J Immunol 1999; 29: 1785-1792.
146. Carmona Arana JA, Seher A, Neumann M, Lang I, Siegmund D, Wajant H. TNF Receptor-Associated Factor 1 is a Major Target of Soluble TWEAK. Front Immunol 2014; 5: 63.
147. Swee LK, Ingold-Salamin K, Tardivel A, Willen L, Gaide O, Favre M et al. Biological activity of ectodysplasin A is conditioned by its collagen and heparan sulfate proteoglycan-binding domains. J Biol Chem 2009; 284: 27567-27576.
148. Wyzgol A, Muller N, Fick A, Munkel S, Grigoleit GU, Pfizenmaier K et al. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol 2009; 183: 1851-1861.
149. Muller N, Wyzgol A, Munkel S, Pfizenmaier K, Wajant H. Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization. FEBS J 2008; 275: 2296-2304.
150. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a deathinducing signaling complex. Mol Cell Biol 2003; 23: 1428-1440.
151. Gieffers C, Kluge M, Merz C, Sykora J, Thiemann M, Schaal R et al. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcgamma receptors. Mol Cancer Ther 2013; 12: 2735-2747.
152. Seifert O, Plappert A, Fellermeier S, Siegemund M, Pfizenmaier K, Kontermann RE. Tetravalent antibody-scTRAIL fusion proteins with improved properties. Mol Cancer Ther 2014; 13: 101-111.
153. Rauert H, Wicovsky A, Muller N, Siegmund D, Spindler V, Waschke J et al. Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2). J Biol Chem 2010; 285: 7394-7404.
154. Haswell LE, Glennie MJ, Al-Shamkhani A. Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur J Immunol 2001; 31: 3094-3100.
155. Stone GW, Barzee S, Snarsky V, Kee K, Spina CA, Yu XF et al. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol 2006; 80: 1762-1772.
156. Kanagavelu S, Termini JM, Gupta S, Raffa FN, Fuller KA, Rivas Y et al. HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T cell mediated anti-viral immunity. PLoS One 2014; 9: e90100.
157. Kanagavelu SK, Snarsky V, Termini JM, Gupta S, Barzee S, Wright JA et al. Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine. Vaccine 2012; 30: 691-702.
158. Morris NP, Peters C, Montler R, Hu HM, Curti BD, Urba WJ et al. Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. Mol Immunol 2007; 44: 3112-3121.
159. Sharma S, de Vries EG, Infante JR, Oldenhuis CN, Gietema JA, Yang L et al. Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Invest New Drugs 2014; 32: 135-144.
160. Luo Y, Lu Z, Raso SW, Entrican C, Tangarone B. Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcgamma receptors. MAbs 2009; 1: 491-504.
161. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113: 3716-3725.
162. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005; 23: 41-51.
163. Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER et al. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods 2014; 65: 114-126.
164. White AL, Dou L, Chan HT, Field VL, Mockridge CI, Moss K et al. Fcgamma receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization. J Immunol 2014; 193: 1828-1835.